Tip os
Log ind

Zealand sees big potential for SBS drug

Britt.jpg Top picks in English:

Zealand Pharma sees a significant potential for the candidate drug glepaglutide for treatment of short bowel syndrome (SBS), which has just delivered promising phase II results. The biotech company plans to win approval and market the drug on its own, hoping it can compete with a similar product from Shire, says CEO Britt Meelby Jensen.

Novo Nordisk hires new head of Europe

Novo Nordisk flag-version2.jpg Top picks in English:

Novo Nordisk has recruited a former AbbVie manager to lead the company’s European department, which has recently moved from Switzerland to Copenhagen. It is simply cheaper to have the 50 man unit in the Danish capital and according to CEO Lars Fruergaard Jørgensen, it is one of the world’s most attractive cities.

DNB sees huge potential in Norwegian biotech cluster

Norway-based financial services group DNB believes the Oslo Cancer Cluster has developed into one of Europe’s top biotech hubs. Norway’s life science industry is generally speaking more mature than a few years ago, says the group’s senior advisor for healthcare.

ANNONCE


ANNONCE